EE61 Cost Effectiveness of Treating Ivig-Resistant Kawasaki Disease Children with Second Round IVIG Versus Infliximab
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.366
https://www.valueinhealthjournal.com/article/S1098-3015(23)00466-7/fulltext
Title :
EE61 Cost Effectiveness of Treating Ivig-Resistant Kawasaki Disease Children with Second Round IVIG Versus Infliximab
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00466-7&doi=10.1016/j.jval.2023.03.366
First page :
Section Title :
Open access? :
No
Section Order :
11752